All News

Results of a retrospective study conducted in Spain found that dialectical-behavioral therapy skills training can help mitigate polypharmacy in those with borderline personality disorder.

A poster presentation from the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium suggests more research is needed to confirm the optimal treatment algorithms for patients with hepatocellular carcinoma.

Americans who are boosted are 95 times less likely than unvaccinated people to die of COVID-19, the FDA approved the first generic drug for Restasis to treat dry eye syndrome, and CMS is putting a greater focus on health equity for Medicare Advantage and Part D plans.

The Biosimilars Initiative in British Columbia, Canada, mandated patients with certain conditions on the province’s prescription coverage plan to switch from originator etanercept to a biosimilar.

Interim data from a National Cancer Institute Center for Cancer Research study show demonstrated immune reactions in patients with breast cancer following immunotherapy with their own tumor-infiltrating lymphocytes (TIL).

Central Mexican women and women from Yucatán both had risk factors for systemic lupus erythematosus, but they differed in type and degree of risk.

A meta-analysis on first-line treatment for non–small cell lung cancer (NSCLC) in clinical trials revealed that inclusion of dexamethasone along side chemotherapy and PD-L1 inhibitors yielded benefits in this patient population.

Sinonasal CT scores were associated with several prognostic features in the disease course of chronic rhinosinusitis with nasal polyps, including blood eosinophil counts and risk of relapse after endoscopic sinus surgery.

New survey findings reveal a significant association between migraine and irritable bowel syndrome.

Two common models, the CURB-65 and BAP-65, had low predictive value in determining which patients with pneumonic chronic obstructive pulmonary disease would not survive.

The rise in popularity of genetic testing brings along a myriad of challenges ranging from concerns on data privacy to insurance coverage, but, when utilized correctly, it could mark a step forward for significant advancements in individual and population health.

President Biden announced he would bring back the Cancer Moonshot initiative that launched in the Obama administration; the World Health Organization said the Omicron subvariant, BA.2, appears to have the same severity as the original Omicron variant; cases of suicide by drug overdose increased in young people, older adults, and non-Hispanic Black women.

Florida Cancer Specialists physicians discuss why teamwork is essential to ensure that oncologic pharmaceuticals are used safely and effectively so that patients achieve optimal clinical outcomes.

Studies conducted by physicians at Florida Cancer Specialists & Research Institute were featured in poster presentations at ASCO 2022 Gastrointestinal Cancers Symposium.

Florida Cancer Specialists & Research Institute provides the newest cancer therapies, some not yet available elsewhere, through convenient access to clinical trials.

There is a persistent lack of effective treatments for heart failure with preserved ejection fraction (HFpEF), so in this study, investigators examined the impact of an atrial shunt among patients with this disease subtype.

Psoriasis developed in 1 in 4 patients with axial spondyloarthritis (axSpA) across a 6-year span, in which those with both conditions reported greater joint involvement and biologic use than those with only axSpA.

A large international real-world analysis revealed the extent to which the COVID-19 pandemic has impacted the global population of patients with multiple myeloma (MM) and the ability for providers to help patients manage the condition.

Pfizer/BioNTech expected to file for emergency use designation of its COVID-19 vaccine in young children aged 6 months to 5 years; Environmental Protection Agency (EPA) sets limits on power plant emissions of mercury and other hazardous pollutants; Black women at disproportionately greater risk of late-stage cervical cancer diagnosis and death.

As a social determinant of health, transportation barriers and their impact on health-related quality of life (HRQOL) were investigated among persons living with HIV in the Deep South.

The report builds upon existing research into metabolic biomarkers, identifying 14 differential biomarkers in patients with systemic lupus erythematosus and skin involvement.

Geoffrey Boyce, CEO of Array Behavioral Care, discusses Array AtHome’s telebehavioral health services, which are now available to approximately 5 million Humana Medicare Advantage members.

The FDA has cleared the first tubeless automated insulin delivery system with a smartphone app control.

Investigators analyzed 12 categories of workplace agents, but only the composite category of pesticides was found to be linked with developing chronic obstructive pulmonary disease.

Although a number of biomarkers can be used to track features of pulmonary hypertension, no single biomarker is sufficient, according to a new review.

Minority patients and those with low income were more likely than White and high-income counterparts to report adverse outcomes in the management of asthma and eczema.

This represents the approval of the first bispecific antibody to treat wet age-related macular degeneration (AMD) and diabetic macular edema (DME).

A novel Omicron subvariant, BA.2, was found to be 1.5 times more transmissible than the original Omicron strain; analysis finds drugmakers increased list prices by 6.6% at the beginning of the year; alcohol consumption linked with the development of several cancer types.

The Oncology Care Model (OCM) is set to expire June 30, 2022. With no successor on the horizon, respondents to a recent survey by the Community Oncology Alliance (COA) say features such as dedicated navigators and weekend appointments could be reduced or lost if revenues that supported them are eliminated.

Researchers compiled data from studies of oral Evrysdi (risdiplam), Spinraza (nusinersen), and Zolgensma (onasemnogene abeparvovec), finding evidence that risdiplam may be a favorable alternative to nusinersen for type 1 SMA.